"Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care" provides an in-depth review of the state of translational science across all stages of pharmaceutical development with a special focus on personalized health care. This book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, commercialization and much more. It features case studies devoted to the applications of pharmacogenomics, toxicogenomics, and other genetic technologies as they support drug discovery and development.

With chapters written by international authorities in industry and academia, this work is a truly unique presentation of the thoughts and approaches that lead to the development of personalized medicine. Intended for all those involved in clinical translational research, this book is the ideal resource for scientists searching for the applications, strategies and successful approaches of translational science in pharmaceutical development.
Provides case studies in applications of pharmacodynamic and predictive markers in drug development in oncology, autoimmunity, respiratory diseases and infectious diseasesShows how to identify potential new therapeutic targets in different diseases and provides examples of potential new disease indications for life cycle management of drugsAuthored by leading international experts from industry and academia

Auto-immune diseases such as systemic lupus erythematosus (SLE), Sjoegren's syndrome, psoriasis, scleroderma (SSc) and myositis are heterogeneous disorders that result from interactions between genetic and environmental factors. Type I interferons (IFNs), especially IFN- / , have multiple biological functions including anti-viral and anti-bacterial properties, immuno-modulation, anti-proliferation, and intensive studies over decades have also revealed important roles in auto-immunity and cancer. Sustained Type I IFN elevation has been implicated in immune responses against self-antigens and tissue damage, which has led to the hypothesis that type I IFN might play a critical role in the pathogenesis of some auto-immune and inflammatory diseases. This book provides an overview of many key topics surrounding type I IFNs, beginning with detailed discussion of the type I IFN signalling pathway, the interplay between components that regulate this pathway, its involvement in auto-immunity, and a detailed review of the roles of type I IFNs in a series of well characterised inflammatory and auto-immune diseases.